Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Prognostic Genomic Biomarkers in Patients With Localized Prostate Cancer

Prognostic Genomic Biomarkers in Patients With Localized Prostate Cancer Regional Adoption of Commercial Gene Expression Testing for Prostate Cancer Original Investigation Research Invited Commentary Prognostic Genomic Biomarkers in Patients With Localized Prostate Cancer Is Rising Utilization Justified by Evidence? Daniel W. Lin, MD; Peter S. Nelson, MD A diagnosis of localized prostate cancer poses an array of treat- ing, all surrogates for increased access to health care and ment decisions for patients and treating physicians. Prostate resources. cancer is notable for the remarkable diversity in clinical out- The appropriateness of TGBT utilization is a central issue to this report, and ascertainment of appropriate use requires comes that range from an indolent course, with no impact on the patient if left untreated, to linkage to clinical data, which was unfortunately not avail- rapid progression to meta- able. The majority of the HRRs in the highest group were from Related article page 52 static disease and cancer- 1 single state, and the highest utilization, with 50% of pa- specific death. Consequently, treatment options also span con- tients with prostate cancer diagnoses undergoing genomic test- servative approaches, such as active surveillance to radical ing, was in a city with a population of less than 50 000 in 2018. curative therapy that http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Oncology American Medical Association

Prognostic Genomic Biomarkers in Patients With Localized Prostate Cancer

JAMA Oncology , Volume 7 (1) – Jan 25, 2021

Loading next page...
 
/lp/american-medical-association/prognostic-genomic-biomarkers-in-patients-with-localized-prostate-MdRH8Z1sbT
Publisher
American Medical Association
Copyright
Copyright 2020 American Medical Association. All Rights Reserved.
ISSN
2374-2437
eISSN
2374-2445
DOI
10.1001/jamaoncol.2020.6045
Publisher site
See Article on Publisher Site

Abstract

Regional Adoption of Commercial Gene Expression Testing for Prostate Cancer Original Investigation Research Invited Commentary Prognostic Genomic Biomarkers in Patients With Localized Prostate Cancer Is Rising Utilization Justified by Evidence? Daniel W. Lin, MD; Peter S. Nelson, MD A diagnosis of localized prostate cancer poses an array of treat- ing, all surrogates for increased access to health care and ment decisions for patients and treating physicians. Prostate resources. cancer is notable for the remarkable diversity in clinical out- The appropriateness of TGBT utilization is a central issue to this report, and ascertainment of appropriate use requires comes that range from an indolent course, with no impact on the patient if left untreated, to linkage to clinical data, which was unfortunately not avail- rapid progression to meta- able. The majority of the HRRs in the highest group were from Related article page 52 static disease and cancer- 1 single state, and the highest utilization, with 50% of pa- specific death. Consequently, treatment options also span con- tients with prostate cancer diagnoses undergoing genomic test- servative approaches, such as active surveillance to radical ing, was in a city with a population of less than 50 000 in 2018. curative therapy that

Journal

JAMA OncologyAmerican Medical Association

Published: Jan 25, 2021

References